The $1.13 billion loss, equivalent to $2.19 per share, represents a significant expansion from the $512 million loss reported during the same period last year. A primary driver of the deficit was a $485 million goodwill impairment charge linked to the company’s Front Line Care unit. On an adjusted basis, earnings reached 36 cents per share, though management noted that performance was dampened by an unfavorable product mix and non-recurring inventory adjustments.
In section Market Quotes
Baxter Shares Plunge as Q4 Loss Widens to $1.13 Billion
Baxter International reported a deeper-than-expected fourth-quarter loss of $1.13 billion, sending its stock tumbling 15% in premarket trading. Despite achieving sales growth across all business segments, the healthcare giant struggled with impairment charges and operational headwinds that overshadowed its revenue gains.
Operational Headwinds and Segment Growth
Total sales from continuing operations climbed 8% to $2.97 billion, reflecting steady demand across the portfolio. Growth was distributed across the company's core divisions:
- Medical products and therapies revenue rose 6%.
- Healthcare systems and technologies sales increased 5%.
- Pharmaceutical sales grew by 4%.
Comments (0)
No comments yet. Be the first!